AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$132.37
+1.98%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$130.46
From 52W high−48.12%
Volume718322.00
Market cap$6.96B
P/E (TTM)—
P/S (TTM)8.0x
Div yield—
Key dataNov 6, 2026
Open
$130.46
From 52W high
−48.12%
Volume
718322.00
Market cap
$6.96B
ValuationView details →
P/E (Fwd)
75.5x
EV/EBITDA
−47.9x
P/E (TTM)
—
RSI (14)
26.7
MomentumView details →
1D Return
+1.98%
YTD Return
−26.97%
SummaryUpdated Sep 1, 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company founded in 2012 and headquartered in New York. The company went public in 2015 and focuses on developing and commercializing novel therapies for central nervous system (CNS) disorders. Axsome has successfully transitioned from a pure development-stage company to a commercial-stage biopharmaceutical company with multiple approved products generating significant revenue growth.
Similar companies
Latest newsMore news →
Axsome Therapeutics, Inc. reported a quarterly loss of $0.25 per share, compared with a loss of $0.94 per share a year earlier.5d agoAxsome Therapeutics reported third-quarter 2026 net product revenue of $259.7 million, up 52% year over year, and a net loss of $12.9 million.6d agoAxsome Therapeutics announced that it will report its third-quarter 2026 financial results on November 2, 2026, before U.S. markets open, followed by a management conference call at 8:00 a.m. Eastern Time.32d ago